Literature DB >> 25261182

The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?

Denis Nam1, Anita Sadhu1, Jeffrey Hirsh1, James A Keeney1, Ryan M Nunley1, Robert L Barrack1.   

Abstract

The purpose of this study was to determine the percentage of time that patients are therapeutic when prescribed warfarin for chemical thromboprophylaxis following a hip or knee arthroplasty procedure. One hundred eighty-four patients receiving warfarin for 4weeks postoperatively, dosed using a Web-application accounting for patient demographics, INR levels, and concomitant medication use, were included. Patients with a target INR range between 1.7 and 2.7 were therapeutic for only 54.4% of the time (32.5% subtherapeutic, 13.0% supratherapeutic) while patients with a target INR range between 2.0 and 3.0 were therapeutic for only 45.9% of the time (39.2% subtherapeutic, 14.8% supratherapeutic). Patients receiving warfarin for chemical thromboprophylaxis are within their targeted INR range for only a limited period of time during their postoperative course.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coumadin; thromboprophylaxis; total knee arthroplasty; venous thromboembolism; warfarin

Mesh:

Substances:

Year:  2014        PMID: 25261182      PMCID: PMC4324127          DOI: 10.1016/j.arth.2014.08.032

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  32 in total

1.  Venous thromboembolic disease after total hip and knee arthroplasty.

Authors:  Steven B Haas; Robert L Barrack; Geoffrey Westrich
Journal:  Instr Course Lect       Date:  2009

2.  Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors.

Authors:  Benjamin Zmistowski; Camilo Restrepo; Jordan Hess; Darius Adibi; Soltan Cangoz; Javad Parvizi
Journal:  J Bone Joint Surg Am       Date:  2013-10-16       Impact factor: 5.284

Review 3.  Advances in prevention of venous thromboembolic disease after elective hip surgery.

Authors:  G D Paiement; N E Beisaw; W H Harris; S J Wessinger; E M Wyman
Journal:  Instr Course Lect       Date:  1990

4.  Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement.

Authors:  C W Francis; V D Pellegrini; V J Marder; S Totterman; C M Harris; K R Gabriel; M V Azodo; K M Leibert
Journal:  JAMA       Date:  1992-06-03       Impact factor: 56.272

Review 5.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

6.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

7.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

8.  Warfarin for thromboprophylaxis following total joint arthroplasty: are patients safely anti-coagulated?

Authors:  Michael Aynardi; P Benedict Brown; Zachary Post; Fabio Orozco; Alvin Ong
Journal:  J Arthroplasty       Date:  2013-04-19       Impact factor: 4.757

Review 9.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

Review 10.  Current guidelines for total joint VTE prophylaxis: dawn of a new day.

Authors:  R L Barrack
Journal:  J Bone Joint Surg Br       Date:  2012-11
View more
  2 in total

1.  Use of dabigatran vs. warfarin with low-molecular-weight heparin bridging in catheter ablation for atrial fibrillation patients with a low CHADS2 score.

Authors:  Li Hao; Bing Rong; Fei Xie; Ming-Jie Lin; Jing-Quan Zhong
Journal:  Biomed Rep       Date:  2017-03-28

2.  A dedicated anticoagulation clinic does not improve postoperative management of warfarin after total joint arthroplasty.

Authors:  Joshua S Bingham; Christopher G Salib; Kyle Labban; Zachary Morrison; Mark J Spangehl
Journal:  Arthroplast Today       Date:  2018-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.